Research ArticlesReduced Inter- and Intraindividual Variability in Cyclosporine Pharmacokinetics from a Microemulsion Formulation
References (11)
- et al.
Lancet
(1993) - et al.
Clin. Pharmacokinet.
(1986) Transplant Proc
(1986)- et al.
Br. J. Clin. Pharmacol.
(1992) - et al.
J. Pharmacokinet. Biopharm.
(1989)
There are more references available in the full text version of this article.
Cited by (313)
Development of lipid-based SEDDS using digestion products of long-chain triglyceride for high drug solubility: Formulation and dispersion testing
2024, International Journal of PharmaceuticsExploring LIPIDs for their potential to improves bioavailability of lipophilic drugs candidates: A review
2023, Saudi Pharmaceutical JournalDevelopment of self-microemulsifying tablets containing dutasteride for enhanced dissolution and pharmacokinetic profile
2022, International Journal of PharmaceuticsLipid-based formulations to increase cannabidiol bioavailability: In vitro digestion tests, pre-clinical assessment and clinical trial
2021, International Journal of PharmaceuticsOral delivery of proteins and peptides: Challenges, status quo and future perspectives
2021, Acta Pharmaceutica Sinica BCitation Excerpt :Cyclosporine A is the one of the most successful oral peptide products in market. The combination of the cyclic lipophilic undecapeptide with SNEDDS technologies enables the oral bioavailability achieve 19%–40%360. Meanwhile, SNEDDS formulation (Neoral®) overcome the high intra- and inter-patients pharmacokinetics variability in a high percentage of patients by better control of droplet size, increasing intestinal permeability and inhibiting P-glycoprotein efflux and P450 metabolism360.
Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers
2020, European Journal of Pharmaceutics and Biopharmaceutics
Copyright © 1994 Wiley-Liss, Inc., A Wiley Company. Published by Elsevier Inc. All rights reserved.